PDT Partners LLC Increases Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

PDT Partners LLC lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 39.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 352,498 shares of the biopharmaceutical company's stock after acquiring an additional 99,539 shares during the quarter. PDT Partners LLC owned 0.12% of Amicus Therapeutics worth $3,321,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Virtu Financial LLC purchased a new position in shares of Amicus Therapeutics in the third quarter worth about $107,000. Diversified Trust Co lifted its stake in Amicus Therapeutics by 9.7% during the fourth quarter. Diversified Trust Co now owns 81,758 shares of the biopharmaceutical company's stock worth $770,000 after purchasing an additional 7,257 shares during the last quarter. Park Avenue Securities LLC purchased a new stake in shares of Amicus Therapeutics in the 4th quarter valued at $123,000. Avanza Fonder AB bought a new stake in shares of Amicus Therapeutics in the 4th quarter valued at about $157,000. Finally, KBC Group NV grew its holdings in shares of Amicus Therapeutics by 44.4% in the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after purchasing an additional 3,120 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts recently commented on FOLD shares. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. StockNews.com lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, February 20th. Cantor Fitzgerald reissued an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Finally, Wells Fargo & Company cut their price target on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, February 20th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $16.75.

Amicus Therapeutics Stock Up 0.5 %

Shares of FOLD opened at $7.39 on Tuesday. Amicus Therapeutics, Inc. has a 12-month low of $6.20 and a 12-month high of $12.65. The business's 50 day moving average is $8.11 and its 200 day moving average is $9.37. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The company has a market capitalization of $2.27 billion, a PE ratio of -41.06, a price-to-earnings-growth ratio of 1.51 and a beta of 0.79.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.